JADE BIOSCIENCES, INC. (JBIO)
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
📈 **POSITIVE** • Medium confidence analysis (67%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (85%) **Content type:** Clinical